Protection Against a Syngeneic Mammary Adenocarcinoma by Administration of Idiotypic and Anti-Idiotypic Antibodies

A hybridoma secreting a monoclonal antibody (mAb) with specificity for tumor-associated cell surface antigens of a transplantable murine mammary adenocarcinoma (SMC-168) was prepared by fusion of syngeneic C3H/He spleen cells with SP2 myeloma cells. Mice which were pretreated with this mAb (C-73) were significantly resistant to the outgrowth of a tumorigenic dose of SMC-168 cells when compared to controls. The treated nice developed tumor-specific cell-mediated immunity, measured by leukocyte adherence inhibition (LAI), which was equal to that of mice immunized with live tumor cells. The IgG fraction from serum of mice receiving mAb C-73 contained antibodies which would bind to that mAb suggesting the presence of anti-idiotypic antibodies (anti-Id). This binding could be partially inhibited by a soluble l-butanol cell surface extract of SMC-168. Rabbits were immunized with mAb C-73 to produce a polyclonal anti-Id. The purified and absorbed IgG fraction of this serum would bind only to mAb C-73 and not to other mAbs of the same isotype or normal C3H/HeN IgG. Binding of the rabbit anti-Id to mAb C-73 could be partially inhibited by soluble tumor-associated antigen extracted from SMC-168. Mice immunized with this polyclonal anti-Id vaccine developed tumor-specific cell-mediated immunity and were significantly resistant to the outgrowth of a tumorigenic dose of SMC-168.     

Changes in Idiotypic Predominance in the Anti-Arsonate Response by Priming with Anti-Idiotypic Antibodies

The predominant selection of CRI-A-bearing antibodies during the anti-arsonate (ARS) response of A/J mice has been used as a model to analyse the mechanism involved in the process of clonal selection and establishment of predominance. In order to assess the importance of the affinity and adaptability of CRI-A clones in this process, we tested the capability of a minor recurrent idiotype (id-1A3), present in a CRI-Aanti-ARS monoclonal antibody (65-1A3), to develop a normal anti-ARS response. Our results show that the id-1A3 predominance, established by anti-id-1A3 administration was stable during the primary and secondary anti-ARS response and that this predominance occurred concomitantly with low levels of CRI-A. Thus, a change in the idiotype predominance was achieved. In spite of the high levels of id-1A3, the anti-ARS antibody concentration, the affinity values, and the kinetics of the immune response were similar to those of the control group. All these results show that CRI-A clones are not essential in the normal development of the anti-ARS antibody response of A/J mice, and suggest that factors other than affinity could be involved in the establishment of the CRI-A predominance.     

Blocking by Anti-Idiotypic Antibodies of Monoclonal Antibody-Mediated Protection Against Lethal Semliki Forest Virus in Mice

Semliki Forest virus-(SFV) neutralizing monoclonal antibodies (MoAbs), produced after fusion of spleen cells from BALB/c mice and myeloma cell line P3-X63-AG8.653 or SP2/0, were used for anti-idiotypic immunization of female BALB/c mice. Two intracutaneous immunizations (2 × 40 μg per animal), 3 weeks apart, with keyhole limpet haemocyanin-conjugated MoAbs mixed with the saponin Quil A were sufficient to induce high levels of anti-idiotypic antibodies in the circulation of these mice with the capacity to block specifically in vitro MoAb-mediated virus neutralization. Anti-idiotypic antibodies against SFV-neutralizing MoAbs, either passively transferred or actively acquired by immunization, are also able to abrogate (specifically) passive immunity, mediated by critical protective doses of MoAb, in mice against infection with a lethal strain of SFV. Furthermore we confirmed by intervention with anti-idiotypic serum in vivo that an SFV- neutralizing MoAb exerts its greatest protective effect during the first 2 days of infection.     

Protection Against Syngeneic Tumor Grafts Induced by Inoculation with Normal allogeneic Tissues

Subcutaneous injection of normal allogeneic kidney and liver tissues extended survival of DBA/2Cr mice challenged with a lethal dose of syngeneic L5178Y lymphoma cells. Immunization with a combination of tissues from five strains provided far more protection than immunization with tissue from any single strain. It is suggested that the basis of this protective effect is a cross-reactivity or identity between tumor-associated transplantation antigens (TATA) on the L5178Y tumor and non-H-2 alloantigens normally expressed by some allogeneic tissues.     

Idiotypic Multireactivity of ''Natural'' Antibodies

One hundred and twenty IgM-secreting hybridomas derived from unmanipulated 6-day-old BALB/c mice were screened for reactivity with the prototype idiotypic and anti-idiotypic monoclonal antibodies, defining three well established systems, namely TEPC 15:10/13-15, J558:CD3.2, and MOPC 460:F 6(51). Up to 25% of all IgM antibodies reacted with at least one of the six specific ligands, half of the latter being 'monospecific', the others reacting with two or more antibodies. A detailed analysis of the four most multi-reactive clones showed individually specific patterns of reactivity and revealed reactions of the same IgM molecule in idiotypic systems previously studied independently. Furthermore, when tested for functional interactions with syngeneic helper T cells expressing MOPC 460-like clonotypes, one of these antibodies was found to inhibit effector helper activity. The results show the existence of 'natural antibodies' with idiotypic reactivities related to recurrent clonotypes in the strain. They may be either 'specific' or 'multireactive', and might connect idiotypes on T and B cells and on antigenic systems so far studied independently.     

Anti-Idiotypic Antibodies of Reovirus as Biochemical and Immunological Mimics

Among the autoantibodies that are known to play a role in the pathogenesis or autoimmune diseases, antibodies to DNA (anti-DNA) have been the subject of much study. Several interesting observations have resulted. The ability to make antibodies that bind DNA is not abnormal. Normal mice and humans can produce antibodies that bind DNA. On the other hand, large quantities of antibodies to DNA are found in the sera of patients with systemic lupus erythematosus (SLE), and complement-lixing antibodies to double-stranded (ds) DNA cause some of the tissue lesions, especially glomerulonephritis (GN). Why, then, do some individuals make anti-DNA that deposits in glomeruli, skin, and other tissue, resulting in organ damage? It is likely that disease results from a combination of several factors— ability to make pathogenic antibody subsets, inability to downregulate those subsets, and “tissue susceptibility” to injury from those antibodies and their immune complexes. This chapter will focus on the characteristics of pathogenic antibody subsets and their regulation     

Specific Suppression of MLC and CML by Anti-Idiotypic Antibodies in the Mouse

Rabbit antisera directed against idiotypic determinants of alloreactive mouse CBA anti-C57BL/6 T blasts were raised in the following manner: first, a rabbit serum directed against nonspecific CBA blasts cells was prepared by injecting CBA concanavalin A blasts three times at monthly intervals into a rabbit. Second, specific CBA anti-C57BL/6 T lymphoblasts were induced in a mixed lymphocyte culture (MLC), were purified by gravity sedimentation through a fetal calf serum gradient, and, finally, were incubated with the anti-blast serum from the first step. During this incubation, presumably all epitopes of the blast cell population were blocked by anti-blast antibodies, except for the greatly amplified set of CBA anti-C57BL/6 alloreactive idiotypes. The mixture was then injected into fresh rabbits, which were boosted with similar mixtures after 3 and 6 weeks. Blood samples were removed 10 days after each injection. Such sera, when used together with complement, inhibited specifically the stimulation of CBA cells by C57BL/6 antigens in MLC and the CBA anti-C57BL/6 killer cells.     

Heterogeneous Responses of B-Cell Tumours to Anti-Ig and Anti-Idiotypic Antibodies

Anti-Ig antibodies can have two opposing effects on B-cell proliferation, resulting either in stimulation or inhibition. We have examined the proliferative response of 30 B-cell tumours to anti-Ig in the presence and absence of B-cell growth factor. Three reaction patterns were observed. In 12 cases a dose-dependent synergism between anti-Ig and B-cell growth factor was present in the induction of proliferation, in ten cases anti-Ig did not induce any response, and in eight cases anti-Ig suppressed the B-cell growth factor (BCGF)-induced proliferation. Similar responses to anti-Ig were found in the absence of BCGF. When these B-cell tumours were typed for expression of Ig isotypes, HLA class II antigens, several B-cell markers, activation markers, complement receptors, Fc receptors, cell size, and cell cycle phase, no correlation could be found with the proliferative response of these tumour B cells to anti-Ig. T cells or T-cell factors were not involved, because T-cell depletion did not change the tumour B-cell proliferative response to incubation with anti-Ig. The observed inhibition of proliferation did not correlate with the expression of Fc receptors, indicating the involvement of suppressor mechanisms other than the cross-linking of Fc receptors with surface immunoglobulins. Tumour B cells, for which monoclonal anti-idiotypic antibodies (MoAb anti-id) were available, responded to MoAb anti-id in the same way as they did to anti-Ig. In view of the treatment of B-cell malignancies with MoAb anti-id, the question of whether these responses in vitro correlate with in vivo clinical outcome of anti-id therapy is of interest. So far our data show that the proliferative response of B-cell tumours to anti-Ig or MoAb anti-id is heterogeneous and cannot be linked to phenotype, is T cell-independent, and is most likely an intrinsic property of the malignant cell.     

Idiotypic Vaccination: Immunoprotection Mediated by Anti-idiotypic Antibodies with Antibiotic Activity

Anti-Id antibodies were raised in mice against a monoclonal antibody (MoAb KT4) that neutralized the in vitro activity of a Pichia anomala yeast killer toxin. Monoclonal antibody was administered to BALB/C syngeneic mice with different schedules of immunization before intravenous challenge with increasing amounts of yeast killer toxin-sensitive Candida alhicans cells. The course of candidosis was studied in comparison with mice non-immunized and immunized with an isotypc-matched unrelated MoAb subdivided into control groups. Protection was reflected by statistically significant increases in survival rate of mice immunized with MoAb KT4 which showed variable serum levels of yeast killer toxin-like anti-Id antibodies. MoAb KT4 affinity chromatography purified mouse anti-Id antibodies were capable of killing in vitro the yeast ceils of the Candida albicans strain used for the experimental infection.
This is the first report of antimicrobial protection that exploits the role of anti-idiotypic antibodies presumably acting in vivo as antibiotics (idiotypic vaccination).     

Anti-Idiotypic Antibodies in Patients with Different Clinical Forms of Paracoccidioidomycosis

Paracoccidioidomycosis (PCM) is the most prevalent systemic mycosis in Latin America. Patients with PCM show a wide spectrum of clinical and pathological manifestations depending on both host and pathogen factors. Two clinical forms of the disease are recognized: the acute or juvenile form and the chronic or adult form. The major antigenic component of the parasite is a glycoprotein of 43 kDa (gp43). All patient sera present antibodies against gp43 (anti-gp43) and, as demonstrated before by our group, spontaneous anti-idiotypic (anti-Id) antibodies (Ab2) can be detected in patient sera with high titers of anti-gp43. Since it has been postulated that anti-Id antibodies may have a modulating function, we decided to purify and characterize anti-Id antibodies in this system. The possible correlation of Ab2 titers with different clinical forms of disease was also verified. Results showed that purified human anti-Id antibodies (human Ab2) recognized specifically the idiotype of some murine monoclonal anti-gp43 (17c and 3e) but not others (40.d7, 27a, and 8a). Spontaneous anti-Id antibodies were found in all clinical forms of disease. The majority of patients (88%, n = 8) with the acute form of PCM had high titers of Ab2. However, among patients with the multifocal chronic form of the disease, only 29% (n = 14) had high titers of Ab2; 70% (n = 10) of patients with the unifocal chronic form had low titers of Ab2. A correlation between Ab2 titers and anti-gp43 titers was observed before and during antimycotic treatment. Our results suggest that titers of anti-Id antibodies correlate with the severity of PCM in humans.     

单克隆的抗-HBs在同系鼠体内诱导抗-HBs的观察

作者采用BALB/c鼠的抗-HBs单克隆抗体(Ab_1)作为抗原,免疫同系BALB/c小鼠,使其在自身体内产生Ab_2,观察了由Ab_2诱导的Ab_3的消长情况。经测定其血清,免疫小鼠在第7天出现Ab_2,随后第9天、第19天出现Ab_2的显著增高。Ab_3的出现是在第9天,随后在第11天,第17天和第21天出现增高现象。Ab_2与Ab_3的量的变化,呈周期性消长。一般说来,当Ab_2增高时,Ab_3减低;若Ab_2降低,则Ab_3增高。实验过程中,还发现Ab_3能与外界进入体内的HBsAg结合。上述实验中出现的Ab_2和Ab_3之间的相互刺激和相互中和的现象,表明是小鼠体内自身的抗个体型抗体的调节作用的结果,因而出现了上述周期性的动态变化,支持体内存在着一个个体型——抗个体型免疫网络的理论,本文依据实验事实,认为传统的被动免疫方法,在一定条件下,也能诱导出主动免疫。     

Structural Studies of Induced Antibodies with Defined Idiotypic Specificities

The heavy (H) chains of three anti-streptococcal group A carbohydrate antibodies (anti-SACHO) of restricted heterogeneity, elicited in inbred Sprague-Dawley rats, were subjected to 40 cycles of automated Edman degradation. All three antibody H-chain preparations had an identical amino acid sequence and were classified as a variant of the V_HIII subgroup of immunoglobulin H chains. A comparison of the H-chain sequence of these antibodies with that of pooled rat gamma chains suggests that a very minor population of H chains (closely related to the V_HIII subgroup) has been 'recruited' as a consequence of this immunization. This observation further supports the notion that 'framework' and 'specificity' or "hypervariable regions" are closely linked.     

Detection of Cells Producing Anti-Idiotypic Antibody to Thyroid Stimulating Hormone-Reactive Antibodies

BALB/c mice were immunized either with bovine (b) or human (h) thyroid stimulating hormone (TSH) or with one of several mouse monoclonal anti-hTSH antibodies. The binding of biotinylated mouse monoclonal anti-hTSH to sections of spleen, kidney, liver and lung was assessed with fluorescein isothiocyanate labelled avidin. Clusters of cells in the spleens of mice immunized with bTSH bound the labelled monoclonal anti-TSH. We suggest that these cells synthesized auto-anti-idiotypic antibodies to anti-TSH.     

Detection of Cells Producing Anti-Idiotypic Antibody to Thyroid Stimulating Hormone-Reactive Antibodies

BALB/c mice were immunized either with bovine (b) or human (h) thyroid stimulating hormone (TSH) or with one of several mouse monoclonal anti-hTSH antibodies. The binding of biotinylated mouse monoclonal anti-hTSH to sections of spleen, kidney, liver and lung was assessed with fluorescein isothiocyanate labelled avidin. Clusters of cells in the spleens of mice immunized with bTSH bound the labelled monoclonal anti-TSH. We suggest that these cells synthesized auto-anti-idiotypic antibodies to anti-TSH.     

Production of BALB/c Anti-Idiotypic Antibodies Against the BALB/c Myeloma Protein 315 Does Not Require an Intact Ligand-Binding Site

To determine whether the ligand-binding site of the BALB/c myeloma protein 315 is essential for the anti-idiotypic response in syngeneic animals, 17 BALB/c mice were immunized with M315 that had been affinity-labeled with bromo-acetyl-DNP-L-lysine (BADL). Essentially all the active sites of M315 were blocked by the affinity label. Fourteen mice produced antibodies that reacted with an idiotypic determinant localized in the Fv fragment of M315, but this idiotype was not part of the DNP-lysine-binding site, and it was absent from L315 and H315 chains. Two groups of BALB/c mice were immunized with nonaffinity-labeled M315, to determine whether the same idiotype was recognized with this immunogen. All animals in the group that received the most prolonged immunization produced antibodies that could be divided in two populations: about 75% were directed against the site-associated idiotype, and the rest reacted with the nonsite idiotype. The other group produced antibodies exclusively specific for the site. Thus, the site-associated idiotype of M315 is not essential for the antibody response of BALB/c mice against M315, and M315 carries at least two different idiotypes that can be recognized by B cells of syngeneic animals.     

Pathogenic Anti-DNA Antibodies in SLE: Idiotypic Families and Genetic Origins

We have adopted an idiotypic approach to study the double stranded DNA (dsDNA) binding antibodies of systemic lupus erythematosus (SLE). Three anti-idiotypic reagents, 8.12, 31, and F4, identify cross reactive idiotypes that are each expressed on anti-dsDNA antibodies in the sera of many patients with SLE. These idiotypic antibodies are implicated in the pathogenesis of SLE as they are present in immune complex deposits in the kidneys of patients with SLE glomerulonephritis. The autoantibody associated idiotypes are also expressed on antibodies that do not bind DNA. We are investigating the origin of the pathogenic anti-dsDNA antibodies of SLE by comparing the autoantibodies, the antibodies to foreign antigens, and the myeloma proteins that express each SLE associated idiotype. In conjunction with serological analysis of these idiotypic systems, molecular genetic studies indicate that both the 8.12 and the 31 autoantibody associated idiotypes may be germline encoded, while the F4 idiotype is generated by somatic mutation. The data further suggest that the antigenic specificity of the pathogenic anti-DNA antibodies of SLE is acquired through somatic mutation of germline immunoglobulin genes. By studying the regulation of genes capable of encoding pathogenic autoantibodies, in both SLE patients and non-autoimmune individuals, we may be able to elucidate the pathogenesis of autoimmune disease and begin to design more effective therapeutic interventions.     

Idiotypic Restriction of Murine Monoclonal Antibodies to a Defined Antigenic Region of Human Thyroglobulin

In previous studies, we demonstrated that anti-human thyroglobulin (hTg) autoantibodies in patients with thyroid disorders exhibit a restricted epitopic specificity towards antigenic region II defined by its reactivity with four murine monoclonal antibodies (mAb 3, 6, 10, 15). To analyze the relationships between epitopic specificity and idiotypic expression of these mAb, two polyclonal anti-idiotypic sera were generated in rabbits by immunization with F(ab')₂ fragments of mAb 3 and mAb 10. These anti-idiotypic preparations (AI 3 and AI 10) were tested against a panel of hTg-mAb produced in different strains of mice (HR BIOZZI and BALB/c). The idiotypic analysis showed that AI 3 and AI 10 specifically recognized framework-associated idiotopes as well as paratope-associated idiotopes shared by region II mAb. These results demonstrate that specificity for region II was strongly associated with a restricted idiotype suggesting a high sequence homology between V regions. In addition, naïve BALB/c mice immunized with AI 3 or AI 10 produced anti-hTg (Ab3) antibodies that recognize region II epitopes. These latter findings reveal that anti-Id contain a population of Ab2β carrying the internal image of region II epitopes.     

Phenotypic and Functional Changes of Tumour Cells from Patients Treated with Monoclonal Anti-Idiotypic Antibodies

In this paper data are presented indicating that immunotherapy with monoclonal anti-idiotypic antibodies (MoAb anti-id) can provoke different responses in the B-cell tumour concerned. With respect to the course of disease during and after immunotherapy, the in vitro findings may very well explain the in vivo observations in the two patients (D.E.F., B.O.R.) with B-cell chronic lymphocytic leukaemia (B-CLL) who were treated with MoAb anti-id. After initial tumour reduction, there was a recurrence of tumour cells with altered functional and phenotypic properties. In both cases the recurring tumour cells still expressed the same idiotype. In one patient (D.E.F.) the phenotypic changes (a surface Ig change from IgM, IgG, IgA, and IgD to weakly positive IgM and IgD) and functional changes (a 10-fold increase in [3H]thymidine uptake and a decreased idiotype secretion in vitro), together with the in vivo findings with respect to the course of disease--at relapse an impressive tumour regrowth rate with constant serum idiotype level--suggest that immunoselection might have taken place favouring the survival and relapse of a less mature, more aggressive tumour cell population with a lower idiotype expression. In the second patient (B.O.R.), the phenotypic changes (an isotype change from IgM and IgD to IgM with the loss of IgD, and a gradual decrease in expression of CD19 and CD24) and functional changes (a 10-fold increase of idiotype secretion in vitro), together with the in vivo finding that the serum idiotype level had increased 25-fold compared with the preimmunotherapy serum level with comparable tumour load, strongly suggest an immunotherapy-induced differentiation of the malignant B cell. We also describe an increased expression of CD74, detected by MoAb BoM22, on the recurring tumour cells of patient B.O.R., whereas the expression of HLA-DP, -DQ and -DR did not change. The significance of this finding is unclear.